Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.
Inflammatix initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Inflammatix was founded in 2016 by Timothy Sweeney and Jonathan Romanowsky. The company is headquartered in Burlingame, California.
Inflammatix's HostDx Sepsis and HostDx Fever tests use proprietary machine learning algorithms that incorporate the expression of multiple immune genes (host response) to identify the presence of bacterial or viral infections and to determine if a patient has or is likely to develop sepsis.
Inflammatix's ViraBac EZ test, which reads gene expression patterns in the immune system to identify whether a suspected infection is bacterial or viral. ViraBac EZ is intended to help physicians quickly and accurately determine whether to prescribe antibiotics in ambulatory settings.
Inflammatix's system is designed to read mRNA and analyze the results using a machine learning algorithm to produce answers in less than 30 minutes.
Inflammatix is backed by Khosla Ventures, Northpond Ventures, BARDA, D1 Capital Partners, Think.Health Ventures, Grey Sky Venture Partners, and others. The company raised a contract extension of $12.1M on Nov 18, 2021. This brings Inflammatix's total funding to $149.9M to date.